The U.S. Food and Drug Administration approved Genentech's Lunsumio VELO (mosunetuzumab-axgb) as a subcutaneous formulation for treating adult patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE